SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000926617-24-000009
Filing Date
2024-03-28
Accepted
2024-03-28 16:50:32
Documents
15
Period of Report
2024-03-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K awh-20240328x8k.htm   iXBRL 8-K 73829
2 EX-99.1 awh-20240328xex99_1.htm EX-99.1 250321
3 GRAPHIC awh-20240328xex99_1g001.jpg GRAPHIC 4677
  Complete submission text file 0000926617-24-000009.txt   470294

Data Files

Seq Description Document Type Size
4 EX-101.SCH awh-20240328.xsd EX-101.SCH 2550
5 EX-101.LAB awh-20240328_lab.xml EX-101.LAB 15612
6 EX-101.PRE awh-20240328_pre.xml EX-101.PRE 11194
18 EXTRACTED XBRL INSTANCE DOCUMENT awh-20240328x8k_htm.xml XML 5016
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 24799972
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)